Summary of burst release from LFX and MFX attachments.

<p>Summary of burst release from LFX and MFX attachments.</p

(a) Photograph of a commercial IOL cross-section and (b) schematic diagram of proposed peripheral drug-eluting attachment to a commercial IOL.

<p>(a) Photograph of a commercial IOL cross-section and (b) schematic diagram of proposed peripheral drug-eluting attachment to a commercial IOL.</p

Summary of burst release from all films.

<p>Summary of burst release from all films.</p

Cumulative release and daily release profiles from LFX attachments.

<p>High loaded attachments (20% and 25%) exhibited high initial burst that released most drug in 24 h. Only 3% and 5% sustained for 14 days.</p

Spray coating process that moves the IOL conjugate-designed mandrel towards the drug-polymer stream.

<p>Spray coating process that moves the IOL conjugate-designed mandrel towards the drug-polymer stream.</p

Surface morphologies of IOL attachment.

<p>SEM images of (a) neat PLC, (b) LFX loaded PLC attachment, (c) MFX loaded PLC attachment. Cross section images of attachment with hook structures: (d) PLC-LFX and (e) PLC-MFX.</p

Cumulative release and daily release profiles from MFX attachments.

<p>All attachments suffered from drug exhibited low drug release.</p

Hydrophilicity comparison of PLC-LFX, PLC-MFX and neat PLC films using contact angle measurement.

<p>Hydrophilicity comparison of PLC-LFX, PLC-MFX and neat PLC films using contact angle measurement.</p

Surface morphology of DCM films.

<p>SEM micrographs of 15%, 20% and 25% LFX loaded films (a, b, c) and 15%, 20% and 25% MFX loaded films (d, e, f).</p

Histology images of the iris and ciliary body with immunohistochemistry stain.

<p>(A and C) Eye implanted with prednisolone acetate loaded microfilm. (B and D) Eye implanted with blank microfilm. White arrows: Positive stain for CD45+ leukocytes. Red arrows: Positive stain for CD4+ T cells.</p